|

Axitinib Clinical Trials

13 actively recruiting trials across 4 locations

Also known as: AG 013736, AG-013736, AG013736, INLYTA, Inlyta

Other9 trials

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
Phase 1/2
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Phase 2
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Phase 2
CARE1 Pragmatic Clinical Trial
Phase 3
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Birmingham, Alabama1 trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Aurora, Colorado1 trial

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

University of Colorado Cancer Center

Phase 2

Tampa, Florida1 trial

Axitinib + Ipilimumab in Advanced Melanoma

Moffitt Cancer Center

Phase 2

Houston, Texas1 trial

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.